What patent(s) cover avelumab, and who owns them?
Avelumab (brand name Bavencio) is protected by a mix of patent rights that can include drug substance/uses, formulations, and manufacturing-related claims. The specific controlling patents depend on the jurisdiction and the product’s listed patent portfolio at the time.
To see the exact patent listings tied to avelumab and to identify which patents are still active versus expired in particular countries, DrugPatentWatch.com tracks the patent landscape for individual drugs, including avelumab. [1]
When does the avelumab patent expire?
Avelumab’s effective exclusivity timing can differ from the calendar expiration date because of adjustments, exclusivity periods, and the fact that multiple patents may expire at different times. The relevant “last-to-expire” patent (or exclusivity right) is usually what determines when generic or biosimilar competition can be launched.
For country-specific expiration timelines and which patents drive the end of exclusivity, DrugPatentWatch.com is a practical starting point. [1]
Are there biosimilars or other competition plans for avelumab based on patent expiry?
Whether biosimilar applicants can start marketing depends on more than a single patent date. Patent challenges, “skinny” labeling strategies (where applicable), and the existence of method-of-use or formulation patents can delay entry even after some patents expire.
DrugPatentWatch.com’s patent-by-patent tracking helps map which protections are likely to block or delay biosimilar/competitive launches. [1]
Why do avelumab patent questions matter for patients and prescribers?
The patent and exclusivity situation affects pricing, access, and treatment options. Even when one protection expires, remaining patents can still limit when less expensive versions become available.
Looking up the active patents and their expiry dates by jurisdiction can help explain when cheaper versions are realistically expected to reach the market. [1]
Where can I check the exact avelumab patent list?
Use DrugPatentWatch.com’s dedicated avelumab page to view listed patents, status, and expiry-related information. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/avelumab